Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 12, 2025

Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders

Sirius Therapeutics has secured around $50m in a Series B2 funding round for the clinical development of small interfering RNA (siRNA) therapeutics targeting cardiometabolic disorders.

The company has secured approvals to commence Phase I trials of SRSD216, designed to treat hyperlipoproteinemia in individuals with atherosclerotic cardiovascular conditions. Credit: Ali Hajiluyi on Unsplash.